Results 51 to 60 of about 5,892 (166)

An Investigation of the Factors Reducing the Use of Hospital Services: A Systematic Review

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aims Hospital service utilization has declined in many health systems due to policy shifts, limited resources, and alternative care approaches. This study aimed to systematically review the factors contributing to a reduction in the use or volume of hospital services.
Sedighe Sadat Tabatabaei Far, Majid Alizadeh, Erfan Kharazmi, Zahra Kavosi   +3 more
wiley   +1 more source

Tolvaptan for paraneoplastic SIADH in small cell lung cancer: a scoping review

Cancer Treatment and Research Communications
Background: Hyponatremia due to the syndrome of inappropriate antidiuretic hormone (SIADH) occurs in approximately 25 % of patients with small cell lung cancer (SCLC). Tolvaptan has emerged as a promising option to treat SIADH in such patients.
Victoria L. Cammann, Menzi Sheryl, Thomas Fürst, Andreas W. Jehle   +3 more
doaj   +1 more source

Five‐Year CT‐Based Skeletal Muscle Decline Curves in Cirrhosis According to Liver Functional Reserve and Routinely Available Clinical Factors

JGH Open, Volume 10, Issue 10, October 2026.
ABSTRACT Background Sarcopenia is common in cirrhosis and is associated with poor outcomes. We aimed to identify factors associated with longitudinal skeletal muscle loss and to explore estimation of future L3 skeletal muscle index (L3‐SMI) using routinely available clinical variables. Methods This retrospective longitudinal study included 175 patients
Suguru Miida, Hiroteru Kamimura, Hitoshi Yoshiji, Masahito Shimizu, Takumi Kawaguchi, Tetsuya Tsuji, Saori Endo, Hiroki Natsui, Hiroki Maruyama, Hiroyuki Abe, Tadashi Namisaki, Takao Miwa, Dan Nakano, Michiyuki Kawakami, Shuji Terai   +14 more
wiley   +1 more source

Severe tolvaptan-associated hyperglycemia: a case report

Journal of Medical Case Reports
Background Tolvaptan-associated hyperglycemia has rarely been described in literature. Case presentation A 95-year-old East Asian (Chinese) male patient with hyponatremia started on tolvaptan treatment at a dosage of 15 mg per day.
Huihuan Sun, Ping Yang, Lijuan Chen, Ying Zhang, Shudong Liu, Wenxiu Sun   +5 more
doaj   +1 more source

Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan

, 2023
Tolvaptan is an effective drug for the treatment of autosomal dominant polycystic kidney disease, but its use is associated with a significant risk of T-cell-mediated liver injury in a small number of patients.
Mosedale, Merrie, Naisbitt, Dean J, Hammond, Sean, Meng, Xiaoli   +3 more
core   +1 more source

Efficacy and safety of tolvaptan for refractory fluid collection and edema in the terminal cancer patients

Fujita Medical Journal, 2023
Objective: Tolvaptan, a vasopressin V2 receptor antagonist, is an oral diuretic. Patients with terminal cancer develop marked fluid retention, and oral diuretics other than tolvaptan have been used as treatments without clear therapeutic effects. Herein,
Norimasa Tsuzuki, Masanobu Usui, Akihiro Itoh, Akihiko Futamura, Kazuki Imai   +4 more
doaj   +1 more source

Salt Intake and Kidney Outcomes in Older Adults With Chronic Kidney Disease: A Stage‐Specific Cohort Study

Nephrology, Volume 31, Issue 9, September 2026.
ABSTRACT Aim In patients with chronic kidney disease (CKD), salt restriction has been shown to lower blood pressure and proteinuria and to provide kidney protective effects. However, the benefit of salt restriction in older adults with CKD remains unclear, particularly in advanced stages.
Hiroaki Miyauchi, Tatsuhiko Azegami, Takashin Nakayama, Chisato Mitsue, Hirotaka Shibata, Kaori Hayashi   +5 more
wiley   +1 more source

Effect of tolvaptan on acute heart failure with hyponatremia – A randomized, double blind, controlled clinical trial

Indian Heart Journal, 2016
Objectives: To assess the efficacy of tolvaptan in acute heart failure with hyponatremia using a randomized double-blinded placebo-controlled study design. Background: Tolvaptan is a selective vasopressin receptor 2 antagonist.
Elangovan Shanmugam, C.R. Madhu Prabhu Doss, Melvin George, Amrita Jena, Muthukumar Rajaram, Balaji Ramaraj, Karthik Anjaneyan, B. Kanagesh   +7 more
doaj   +1 more source

Development of plant‐derived biomimetic nanoparticles as a novel targeted drug delivery platform

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
Plant‐derived biomimetic nanoparticles (PD‐BNPs) represent a sustainable and biocompatible nanoplatform for targeted drug delivery. This review highlights their therapeutic potential, engineering strategies, and translational challenges toward precision nanomedicine applications. Abstract Plant‐derived biomimetic nanoparticles (PD‐BNPs) have emerged as
Jihad Hasan, Asnaf Nihan Shuvo, Md. Rezaul Karim Sheikh, A. Nayeem Faruqui   +3 more
wiley   +1 more source

Sinusoidal Obstruction Syndrome With Inotuzumab Ozogamicin Combined With Ponatinib for Philadelphia‐Chromosome‐Positive Lymphoblastic Malignancies

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Sinusoidal obstruction syndrome, also known as veno‐occlusive disease (SOS/VOD), can occur after exposure to inotuzumab ozogamicin (InO), a calicheamicin‐based antibody‐drug conjugate. Case Presentation We experienced two cases of SOS/VOD after treatment with InO combined with intermittent administration of ponatinib without ...
Emi Yokoyama, Satoshi Ota, Yasuo Sakurai, Toma Suzuki, Naoki Miyashita, Minoru Kanaya, Koh Izumiyama, Makoto Saito, Masanobu Morioka, Akio Mori, Takeshi Kondo   +10 more
wiley   +1 more source